Trulicity Employer and ICHRA Coverage Navigation: How to Get Dulaglutide Cheaper in 2026

What Does Trulicity Actually Cost Without Coverage?

The average wholesale price for a single 0.75 mg/0.5 mL or 1.5 mg/0.5 mL Trulicity pen runs close to $985 in 2026. FDA labeling confirms dulaglutide is available in four dose strengths: 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg. A standard monthly supply is a 4-pen box, putting uninsured list-price spend above $3,900 per month.

Why List Price Rarely Reflects What You Pay

Pharmacy benefit managers negotiate rebates that can reduce net cost by 30 to 60 percent off list. A 2023 analysis in JAMA found that GLP-1 receptor agonist net prices diverge substantially from list prices after rebates, though those savings flow primarily to plan sponsors rather than patients at the point of sale. Hollenbeck et al., JAMA 2023.

Your actual out-of-pocket expense depends on your plan's formulary tier, whether you have met your deductible, and which co-pay assistance programs you qualify for. Each of those levers is addressable.

The Clinical Justification That Helps Tier Negotiations

Trulicity's coverage breadth is backed by the REWIND trial (N=9,901), which demonstrated a 12% relative risk reduction in major adverse cardiovascular events (MACE) over a median 5.4 years Gerstein et al., Lancet 2019. Plans that cover SGLT2 inhibitors for CV protection typically cannot reasonably exclude dulaglutide without documented clinical justification. That trial data is your physician's strongest argument in a prior authorization appeal.

How Employer Health Plans Cover Trulicity

Most large-group employer plans cover dulaglutide for type 2 diabetes, though formulary placement and prior authorization (PA) requirements vary widely by pharmacy benefit manager (PBM).

Formulary Tiers: Where Trulicity Usually Lands

• Tier 2 (preferred brand): Co-pays typically range from $45 to $90 per fill after deductible.
• Tier 3 (non-preferred brand): Co-pays range from $90 to $150 or higher; some plans apply co-insurance of 20 to 40 percent.
• Specialty tier: A minority of plans place all GLP-1 agonists on a specialty tier with co-insurance up to 30 percent of the negotiated price.

The American Diabetes Association's 2025 Standards of Care designate GLP-1 receptor agonists as preferred agents for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease or high CV risk ADA Standards of Care 2025. That guideline language is directly quotable in a PA letter.

Prior Authorization: What Employers Require

Most PBMs require at least one of the following before approving Trulicity:

1. A confirmed diagnosis of type 2 diabetes (ICD-10 E11.x).
2. Documentation that metformin was tried and either failed or was contraindicated.
3. An HbA1c above a threshold (commonly 7.5% or 8.0%).
4. Prescriber attestation that the indication matches FDA-approved labeling.

The ADA's 2025 Standards state: "For patients with type 2 diabetes and established cardiovascular disease, GLP-1 receptor agonists with proven cardiovascular benefit are recommended as part of the glucose-lowering regimen." ADA Standards of Care 2025. Printing that sentence into the PA cover letter accelerates approval at most major PBMs.

Step Therapy Requirements

Some employer plans require patients to try and fail on a first-line GLP-1 (often semaglutide 0.5 mg or exenatide) before approving dulaglutide. If your plan has a step therapy protocol, document the reason for switching. A published meta-analysis of GLP-1 trials found that dulaglutide and semaglutide have comparable HbA1c reductions, so the clinical argument for bypassing step therapy is typically drug-specific tolerability, not efficacy Zhu et al., Front Endocrinol 2022.

ICHRA Coverage and Trulicity: A Practical Walkthrough

Individual Coverage Health Reimbursement Arrangements (ICHRAs) let employers reimburse employees tax-free for individual health insurance premiums and, in some plan designs, qualifying medical expenses including prescription cost-sharing.

What ICHRA Pays For

An ICHRA reimburses the premium you pay for an ACA-compliant individual or family plan. If that plan covers Trulicity, the ICHRA effectively covers the premium portion of the cost. Some employers also offer an integrated HRA or a "medical expense" ICHRA that reimburses out-of-pocket prescription costs directly, though that design is less common.

The IRS confirmed in Notice 2019-45 that HRA funds can be used for premiums and qualifying medical expenses, a framework later expanded for ICHRAs under the final rule published in the Federal Register HHS/DOL/Treasury ICHRA Final Rule 2019. Because dulaglutide is an IRS-recognized prescription drug, any ICHRA design that reimburses qualifying medical expenses covers Trulicity prescriptions.

Choosing the Right ACA Plan Under ICHRA

When you receive ICHRA dollars, you shop for an individual plan on the exchange or off-exchange. Your goal is to find a plan that places Trulicity on its formulary at the lowest tier possible. Steps:

1. Use Healthcare.gov's drug search tool or call the insurer's pharmacy benefits line before enrolling.
2. Compare Silver-tier plans first. Silver plans balance premium and deductible in a range that often makes specialty drugs more accessible after deductible.
3. Confirm whether the plan uses a major PBM (Express Scripts, CVS Caremark, OptumRx) and whether that PBM lists dulaglutide as preferred.
4. Ask whether the plan counts Lilly savings card payments toward your deductible (some do not, per accumulator adjustment programs).

Accumulator Adjustment Programs and ICHRA Interaction

Accumulator adjustment programs (AAPs) prevent manufacturer co-pay card payments from counting toward your deductible or out-of-pocket maximum. A 2022 study in the American Journal of Managed Care found that AAPs shifted an average of $2,000 to $5,000 in annual costs back to patients on specialty drugs Doshi et al., AJMC 2022. If your ICHRA-selected plan uses an AAP, Lilly's savings card saves money each fill but does not accelerate deductible accumulation. Factor that into your plan-selection math.

Lilly's Savings Programs for Trulicity in 2026

Eli Lilly runs multiple patient assistance and co-pay programs. Eligibility rules differ by insurance status.

Lilly Savings Card (Commercially Insured Patients)

The Lilly Savings Card for Trulicity caps monthly out-of-pocket costs at $25 for eligible patients with commercial insurance (employer or individual plans purchased off-exchange). The card is not valid for Medicare, Medicaid, or other government-funded plans. Patients can activate the card at LillyCares.com or through their pharmacy.

The savings card applies regardless of formulary tier, meaning even patients on a non-preferred Tier 3 plan pay no more than $25 per monthly fill while the card is active.

Lilly Insulin Value Program vs. Trulicity

The Lilly Insulin Value Program caps insulin costs at $35 per month but does not apply to Trulicity. Patients sometimes conflate the two programs. Trulicity uses the separate Lilly Savings Card program described above.

Lilly Cares Foundation (Uninsured or Underinsured)

For patients without commercial insurance, the Lilly Cares Foundation Patient Assistance Program provides Trulicity at no cost to qualifying patients who meet income criteria (generally at or below 400% of the federal poverty level). Applications are processed through LillyCares.com. Processing typically takes two to four weeks.

340B Covered Entity Pharmacies

Federally Qualified Health Centers and other 340B-covered entities purchase drugs at a significant discount and may dispense Trulicity to eligible patients at substantially reduced cost. HRSA administers the 340B program [HRSA 340B Program Overview](https://www.hrsa.gov/ opdiv/340b). Patients who receive care at a Federally Qualified Health Center should ask whether the center's pharmacy participates.

HSA and FSA Eligibility for Trulicity

Trulicity purchased with a valid prescription is a qualified medical expense under IRS Publication 502, making it eligible for payment with Health Savings Account (HSA) or Flexible Spending Account (FSA) funds. IRS Publication 502 (2025).

How HSA Payments Work With Employer Coverage

If your employer-sponsored plan has a high-deductible health plan (HDHP) paired with an HSA, you can use HSA dollars to cover Trulicity costs before your deductible is met. In 2026, the IRS HDHP minimum deductible is $1,650 for self-only coverage. Trulicity at list price would exhaust that deductible in a single fill, at which point insurance co-pays apply.

Contribution limits for 2026: $4,300 for self-only HSA coverage and $8,550 for family coverage, per IRS Rev. Proc. 2025-19 IRS Rev. Proc. 2025-19. HSA funds roll over indefinitely and can be invested once the account balance exceeds the plan's cash threshold.

FSA Considerations

FSA funds are use-it-or-lose-it within the plan year (with a limited carryover or grace period). Using FSA dollars for Trulicity makes sense when you know you will fill the prescription within the plan year. The 2026 FSA contribution limit is $3,300 per IRS guidance.

Co-Pay Cards and HSA Interaction

IRS guidance prohibits using HSA funds to cover expenses already reimbursed by a co-pay assistance program. The practical implication: use the Lilly Savings Card first (it pays the co-pay), then use HSA funds only for any remaining out-of-pocket cost. Do not double-dip.

Step-by-Step Coverage Navigation Plan

The following framework applies to patients who have received a Trulicity prescription and need to minimize cost quickly.

Step 1: Confirm Your Formulary Tier

Call the member services number on your insurance card and ask: "What tier is dulaglutide (Trulicity) on my current formulary, and what is my co-pay after deductible?" Request the answer in writing or document the call date and representative name.

Step 2: Check for Prior Authorization Requirements

Ask member services whether a PA is required. If yes, ask for the specific clinical criteria document. Share it with your prescriber the same day. A 2019 study in JAMA Internal Medicine found that PA delays average 1.7 days but can extend to more than two weeks for specialty drugs when documentation is incomplete Chua et al., JAMA Intern Med 2019. Front-loading complete documentation cuts that delay substantially.

Step 3: Apply the Lilly Savings Card Immediately

Even before your PA is resolved, activate the Lilly Savings Card at LillyCares.com. The card is applied at the pharmacy counter and does not require prior authorization approval.

Step 4: Evaluate ICHRA Plan Selection at Open Enrollment

If your employer offers an ICHRA, review ACA plan options 60 days before your current coverage expires. Compare formulary tier placement for dulaglutide across at least three plans. A Silver plan with Trulicity on Tier 2 and a moderate deductible typically produces the lowest annual out-of-pocket cost when combined with the Lilly Savings Card.

Step 5: File an Appeal if Denied

If your PA is denied, your employer plan must offer an internal appeal under ERISA. Submit the ADA 2025 Standards citation above, the REWIND CV outcomes data Gerstein et al., Lancet 2019, and a letter of medical necessity from your prescriber. External appeals are available through your state insurance commissioner if the internal appeal fails.

Trulicity's Clinical Profile: What Employers and PBMs Are Covering

Understanding what dulaglutide does clinically helps when explaining medical necessity to HR departments or PBM reviewers.

Glycemic Efficacy

In the AWARD-1 trial (N=976), dulaglutide 1.5 mg reduced HbA1c by 1.51 percentage points from baseline vs. 0.99 points for exenatide twice daily at 26 weeks Wysham et al., Diabetes Care 2014. The FDA approved the 3 mg and 4.5 mg doses in 2020 based on AWARD-11 data showing additional HbA1c reductions of 0.4 to 0.5 percentage points beyond 1.5 mg Frias et al., Lancet Diabetes Endocrinol 2021.

Cardiovascular Outcomes

REWIND enrolled 9,901 patients with T2DM and either established CVD or CV risk factors. Over a median 5.4 years, dulaglutide reduced the primary MACE endpoint (CV death, non-fatal MI, non-fatal stroke) by 12% vs. Placebo (HR 0.88, 95% CI 0.79 to 0.99, P<0.026) Gerstein et al., Lancet 2019. That outcome data is the reason the ADA lists dulaglutide as a preferred agent for patients with high CV risk.

Weight Effects

Dulaglutide produces modest weight loss. In AWARD-11, the 4.5 mg dose produced a mean weight reduction of 4.7 kg vs. 2.7 kg for 1.5 mg at 36 weeks Frias et al., Lancet Diabetes Endocrinol 2021. Patients seeking more pronounced weight loss may be directed by their physician toward higher-dose semaglutide (Ozempic 2 mg or Wegovy 2.4 mg), which produced 14.9% mean body weight reduction in STEP-1 (N=1,961) Wilding et al., NEJM 2021. The choice between agents depends on clinical priorities and formulary access.

Tolerability

GI adverse effects (nausea, diarrhea, vomiting) affect roughly 20% of patients initiating dulaglutide, typically diminishing after the first four to eight weeks. A pooled analysis of AWARD trials (N=6,005) confirmed that serious GI events occurred in fewer than 1% of participants Barrington et al., Diabetes Obes Metab 2021.

When Trulicity Is Not Covered: Alternatives and Escalation Paths

Occasionally, an employer plan excludes dulaglutide entirely or places it on a non-reimbursable exclusion list. Three options exist.

Therapeutic Substitution Within GLP-1 Class

If the plan covers semaglutide (Ozempic) or liraglutide (Victoza) but not dulaglutide, your prescriber can substitute within the GLP-1 class. The ADA's 2025 Standards list multiple GLP-1 agents as equally appropriate for CV risk reduction ADA Standards of Care 2025.

External Medical Exception Request

Under the No Surprises Act and ERISA, patients can request a medical exception when the plan-preferred drug is clinically inappropriate. Document specific intolerability (for example, persistent nausea requiring emergency care on liraglutide) or a contraindication. The Endocrine Society's clinical practice guidelines on type 2 diabetes management support individualized drug selection based on patient-specific factors Endocrine Society T2DM Guidelines.

Employer Benefits Escalation

HR benefits managers at self-insured employers have direct authority over formulary decisions. If a GLP-1 agonist is excluded from a self-insured plan despite ADA guideline support, a written request to the plan administrator citing ERISA fiduciary obligations and ADA guideline language may produce a coverage exception. Employers increasingly recognize that untreated T2DM carries downstream costs that exceed the drug expense. A study published in Diabetes Care estimated that patients achieving HbA1c <7% incur 18% lower total medical costs over five years compared to those with uncontrolled diabetes Dall et al., Diabetes Care 2010.